Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Cancer/Chemotherapy
Trial Information
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)
Multinational, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Patient Inclusion Criteria
- Cancer patients with metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary
- Initiating a (new) course of chemotherapy with a minimum intent of 3 months therapy
PatientExclusionCriteria
Subject requiring systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic
- Patients at high risk of bleeding
- Severe renal impairment (estimated creatinine clearance < 30 mL/min)
- ECOG (Eastern Cooperative Oncology Group) performance status 3 & 4
- Known hypersensitivity to UFH or LMWH
Cathy Spears, Director Research Oncology
St. Francis Hospital and Health Centers
1500 N Albany Street, Suite 1001
Beech Grove, IN 46107
Phone: 317-782-7819
Fax: 317-782-7828
EMail: cathy.spears@ssfhs.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
